Literature DB >> 1356095

The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes.

A G Hadley1, B Zupanska, B M Kumpel, K A Leader.   

Abstract

Subsets of human lymphocytes were isolated from peripheral blood using magnetic beads coated with anti-CD4, -CD8, -CD19 or -CD56 antibodies to yield T4, T8, B and natural killer (NK) cell suspensions with greater than 95% purity. The functional activity of Fc gamma receptor II (Fc gamma RII) and Fc gamma receptor III (Fc gamma RIII) on these subsets was assessed by measuring rosette formation with red cells sensitized with known levels of either rabbit IgG or human (monoclonal or polyclonal) IgG1 anti-D, IgG3 anti-D or IgG3 anti-c (E-IgG). Lysis of red cells by K cells (mediated by Fc gamma RIII) in antibody-dependent cell-mediated cytotoxicity (ADCC) assays was promoted by polyclonal and some monoclonal antibodies. Using these 'ADCC+' antibodies, minimum red cell sensitization levels required to promote rosette formation with NK cells were 2000 IgG1 or IgG3 molecules/red cell compared to 15,000 IgG1 or 4000 IgG3 molecules/red cell with 'ADCC-' monoclonal antibodies. The greater efficiency of ADCC+ antibodies is consistent with their previously reported ability to bind Fc gamma RIII via CH2 and CH3 domains whereas ADCC- antibodies bind only via CH3 domains. B cells formed rosettes only at high levels of sensitization: approximately 60,000 IgG1 or 20,000 IgG3 anti-D molecules/cell. These data reflect the low affinity of Fc gamma RII for monomeric human IgG. Although over 90% of NK cells bound anti-CD16, and 70% formed rosettes with red cells sensitized with rabbit IgG (30,000 molecules/cell), only 25% of NK cells formed rosettes with E-IgG3 at 100,000 IgG molecules/cell. Approximately 35% of B cells, 10% of T8 cells but no T4 cells formed rosettes with E-IgG (100,000 IgG3 molecules/cell). With T8, B and NK cells, IgG3 anti-D promoted greater rosette formation than IgG1 anti-D at comparable levels of sensitization. Presumably the longer hinge region of IgG3 enabled it to bridge the gap between negatively charged lymphocytes and red cells more efficiently than IgG1.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356095      PMCID: PMC1421682     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  Analysis of human peripheral blood mononuclear cells bearing Fc receptors for the three major immunoglobulin isotypes.

Authors:  L Vaickus; M Robinson; R G Lynch
Journal:  Clin Immunol Immunopathol       Date:  1988-04

2.  Characterization of an IgG2, G2m(23) anti-Rh-D antibody.

Authors:  J M Dugoujon; G G de Lange; A Blancher; S Alie-Daram; Y Marty
Journal:  Vox Sang       Date:  1989       Impact factor: 2.144

3.  Functional interactions of red cells sensitized by IgG1 and IgG3 human monoclonal anti-D with enzyme-modified human monocytes and FcR-bearing cell lines.

Authors:  B M Kumpel; A G Hadley
Journal:  Mol Immunol       Date:  1990-03       Impact factor: 4.407

4.  Fc receptors for IgG1 and IgG3 on human mononuclear cells--an evaluation with known levels of erythrocyte-bound IgG.

Authors:  B Zupańska; E E Thomson; A H Merry
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144

5.  The Fc valency of an immune complex is the decisive factor for binding to low-affinity Fc gamma receptors.

Authors:  R J Klaassen; R Goldschmeding; P A Tetteroo; A E Von dem Borne
Journal:  Eur J Immunol       Date:  1988-09       Impact factor: 5.532

6.  Importance of IgG subclasses of anti-Rh antibodies for the detection of Fc-receptor-bearing human lymphocytes.

Authors:  B Zupańska; K Maślanka; E van Loghem
Journal:  Vox Sang       Date:  1982-11       Impact factor: 2.144

7.  A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation.

Authors:  J Lund; T Tanaka; N Takahashi; G Sarmay; Y Arata; R Jefferis
Journal:  Mol Immunol       Date:  1990-11       Impact factor: 4.407

8.  Targeted cytotoxic cells in human peripheral blood lymphocytes.

Authors:  M A Garrido; P Perez; J A Titus; M J Valdayo; D F Winkler; S A Barbieri; J R Wunderlich; D M Segal
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

9.  Inhibition of human natural killer cell activity by cytophilic immunoglobulin G.

Authors:  A Sulica; M Gherman; C Galatiuc; M Manciulea; R B Herberman
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

10.  Heterogeneity in the ability of IgG1 monoclonal anti-D to promote lymphocyte-mediated red cell lysis.

Authors:  B M Kumpel; K A Leader; A H Merry; A G Hadley; G D Poole; A Blancher; D Goossens; N C Hughes-Jones; B A Bradley
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

View more
  7 in total

1.  Plasma half-lives and bioavailability of human monoclonal Rh D antibodies BRAD-3 and BRAD-5 following intramuscular injection into Rh D-negative volunteers.

Authors:  J Goodrick; B Kumpel; D Pamphilon; I Fraser; G Chapman; B Dawes; D Anstee
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

2.  Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes.

Authors:  R G Bredius; C A Fijen; M De Haas; E J Kuijper; R S Weening; J G Van de Winkel; T A Out
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

3.  Pyrosequencing for classification of human FcγRIIIA allotypes: a comparison with PCR-based techniques.

Authors:  Ksenia Matlawska-Wasowska; James M Gale; Christian K Nickl; Parisa Khalili; Brian Shirley; Bridget S Wilson; Mohammad A Vasef; Stuart S Winter
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

4.  Antibody-mediated immunosuppression can result from RBC antigen loss independent of Fcγ receptors in mice.

Authors:  Amanda Mener; Seema R Patel; Connie M Arthur; Sean R Stowell
Journal:  Transfusion       Date:  2018-11-26       Impact factor: 3.157

5.  Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16).

Authors:  B M Kumpel; M De Haas; H R Koene; J G J Van De Winkel; M J Goodrick
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

6.  Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma.

Authors:  Thomas Han; Ussama M Abdel-Motal; De-Kuan Chang; Jianhua Sui; Asli Muvaffak; James Campbell; Quan Zhu; Thomas S Kupper; Wayne A Marasco
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

Review 7.  Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.

Authors:  Veena A Thomas; Joseph P Balthasar
Journal:  Antibodies (Basel)       Date:  2019-12-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.